SNDX insider transaction filings
Syndax Pharmaceuticals Inc — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-09. Screen SNDX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-09 | 4 | Metzger Michael A — Chief Executive Officer, Director | Option exercise (M): 32,375 @ $6.38 · Sale (S): 32,375 @ $24.24 · Option exercise (M): 32,375 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Botwood Nicholas A.J. — Head of R&D, CMO | Option exercise (M): 22,515 @ $13.82 · Sale (S): 34,280 @ $18 · Option exercise (M): 31,235 @ $13.82 · Sale (S): 31,235 @ $18.14 · Option exercise (M): 22,515 (derivative) @ $0 · Option exercise (M): 31,235 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Goldan Keith A. — Chief Financial Officer | Sale (S): 1,177 @ $18.99 | EDGAR |
| 2026-06-02 | 4 | Metzger Michael A — Chief Executive Officer, Director | Sale (S): 6,847 @ $18.99 | EDGAR |
| 2026-02-10 | 4 | Metzger Michael A — Chief Executive Officer, Director | Sale (S): 17,159 @ $21.03 | EDGAR |
| 2026-02-10 | 4 | Goldan Keith A. — Chief Financial Officer | Sale (S): 3,410 @ $21.03 | EDGAR |
| 2026-02-06 | 4 | Metzger Michael A — Chief Executive Officer, Director | Grant/award (A): 73,000 @ $0 · Grant/award (A): 144,600 @ $0 · Sale (S): 7,412 @ $20.62 · Grant/award (A): 440,000 (derivative) @ $20.43 | EDGAR |
| 2026-02-06 | 4 | Goldan Keith A. — Chief Financial Officer | Other (J): 1,219 @ $8.48 · Grant/award (A): 21,500 @ $0 · Grant/award (A): 30,750 @ $0 · Sale (S): 2,082 @ $20.62 · Grant/award (A): 118,000 (derivative) @ $20.43 | EDGAR |
| 2026-02-06 | 4 | Jarrett Jennifer — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-02-06 | 4 | Huber Martin H. Jr. — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-02-06 | 4 | Botwood Nicholas A.J. — Head of R&D, CMO | Grant/award (A): 24,000 @ $0 · Grant/award (A): 36,000 @ $0 · Grant/award (A): 144,700 (derivative) @ $20.43 | EDGAR |
| 2026-02-06 | 4 | Rizo Aleksandra — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-02-06 | 4 | Legault Pierre — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-02-06 | 4 | Katkin Keith — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-02-06 | 4 | Podlesak Dennis — Director | Grant/award (A): 48,000 @ $0 | EDGAR |
| 2025-12-01 | 4 | Goldan Keith A. — Chief Financial Officer | Gift (G): 1,224 @ $0 | EDGAR |
| 2025-09-08 | 4 | Metzger Michael A — Chief Executive Officer, Director | Option exercise (M): 157,307 @ $10.90 · Sale (S): 157,307 @ $16.41 · Option exercise (M): 157,307 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Podlesak Dennis — Director | Option exercise (M): 19,200 @ $7.20 · Sale (S): 19,200 @ $14.19 · Option exercise (M): 19,200 @ $7.20 · Sale (S): 19,200 @ $15.54 · Option exercise (M): 19,200 @ $7.20 · Sale (S): 19,200 @ $15.84 · +4 more | EDGAR |
| 2025-08-07 | 4 | Goldan Keith A. — Chief Financial Officer | Other (J): 1,226 @ $8.43 | EDGAR |
| 2025-07-18 | 4 | Goldan Keith A. — Chief Financial Officer | Sale (S): 1,296 @ $9.29 | EDGAR |
| 2025-07-18 | 4 | Metzger Michael A — Chief Executive Officer, Director | Sale (S): 7,534 @ $9.29 | EDGAR |
| 2025-05-19 | 4 | Goldan Keith A. — Chief Financial Officer | Purchase (P): 3,000 | EDGAR |
| 2025-05-19 | 4 | Botwood Nicholas A.J. — Head of R&D, CMO | Purchase (P): 11,765 @ $8.99 | EDGAR |
| 2025-05-19 | 4 | Huber Martin H. Jr. — Director | Purchase (P): 5,000 @ $8.99 | EDGAR |
| 2025-05-19 | 4 | Katkin Keith — Director | Purchase (P): 10,000 @ $9.11 | EDGAR |
| 2025-03-17 | 4 | Metzger Michael A — Chief Executive Officer, Director | Option exercise (M): 6,074 @ $7.20 · Option exercise (M): 6,074 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Metzger Michael A — Chief Executive Officer, Director | Option exercise (M): 7,814 @ $7.20 · Sale (S): 7,814 @ $15.05 · Option exercise (M): 7,814 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Gallagher Neil — President, Head of R&D | Sale (S): 4,618 @ $15.50 | EDGAR |
| 2025-02-12 | 4 | Goldan Keith A. — Chief Financial Officer | Sale (S): 3,777 @ $15.50 | EDGAR |
| 2025-02-12 | 4 | Metzger Michael A — Chief Executive Officer, Director | Sale (S): 13,288 @ $15.50 | EDGAR |
| 2025-02-07 | 4 | Gallagher Neil — President, Head of R&D | Grant/award (A): 18,500 @ $0 · Grant/award (A): 23,400 @ $0 · Grant/award (A): 110,500 (derivative) @ $14.65 | EDGAR |
| 2025-02-07 | 4 | Goldan Keith A. — Chief Financial Officer | Grant/award (A): 18,500 @ $0 · Grant/award (A): 23,400 @ $0 · Grant/award (A): 110,500 (derivative) @ $14.65 | EDGAR |
| 2025-02-07 | 4 | Metzger Michael A — Chief Executive Officer, Director | Grant/award (A): 60,500 @ $0 · Grant/award (A): 89,000 @ $0 · Grant/award (A): 364,000 (derivative) @ $14.65 | EDGAR |
| 2025-02-07 | 4 | Rizo Aleksandra — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Meury William — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Jarrett Jennifer — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Huber Martin H. Jr. — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Legault Pierre — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Katkin Keith — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-02-07 | 4 | Podlesak Dennis — Director | Grant/award (A): 50,000 @ $0 | EDGAR |
Recent 8-K events — Syndax Pharmaceuticals Inc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-12-19 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SNDX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →